ESH MDS 2024 | Cytogenetic and molecular associations with outcomes in HR-MDS treated with HMAs plus venetoclax
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study exploring cytogenetic and molecular associations with outcomes in high-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMAs) plus venetoclax. As was expected, patients with a complex karyotype and TP53 mutation exhibited a lower response rate and duration of response. However, Prof. Garcia-Manero emphasizes that the data does not mean that HMA plus venetoclax combinations should not be used in poor-risk patients, as responses were superior to HMA alone and may allow these patients to be bridged to transplant. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
